Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis.

ABSTRACT: Immune-related adverse events represent a major hurdle to the success of immunotherapy. The immunological mechanisms underlying their development and relation to antitumor responses are poorly understood. By examining both systemic and tissue-specific immune changes induced by combination anti-CTLA-4 and anti-PD-1 immunotherapy, we found distinct repertoire changes in patients who developed moderate-severe colitis, irrespective of their antitumor response to therapy. The proportion of circulating monocytes were significantly increased at baseline in patients who subsequently developed colitis compared with patients who did not develop colitis, and biopsies from patients with colitis showed monocytic infiltration of both endoscopically and histopathologically normal and inflamed regions of

SUBMITTER: Nahar KJ 

PROVIDER: S-EPMC9675442 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature